Yunis J J, Brunning R D, Howe R B, Lobell M
N Engl J Med. 1984 Sep 27;311(13):812-8. doi: 10.1056/NEJM198409273111302.
Using high-resolution chromosomes of bone-marrow specimens from 105 consecutive adult patients with de novo acute nonlymphocytic leukemia, we found an unusually high degree of complexity in this disorder, which may explain previous difficulties in identifying useful prognostic indicators. Specimens from 99 of the 105 patients were successfully analyzed, and 92 (93 per cent) had a chromosomal defect. Seventeen categories were identified, 12 representing a specific recurrent defect. Three of them have been found to have independent prognostic importance. Patients with an inversion 16 (9 per cent), diagnosed as having M2, M4, or M5b disease according to the morphologic classification of the French-American-British Acute Leukemia Cooperative Study Group, had a uniform and sustained complete remission and a median survival of 25 months. In contrast, 14 patients (14 per cent) with complex chromosomal abnormalities and a diagnosis of M1, M2, M4, M5a, or M6 disease had a very poor prognosis. In 12 of the 14 patients efforts to achieve induction of remission failed, and the group had a median survival of 2.5 months. A third group with a trisomy 8 as the single defect (11 per cent) had an intermediate prognosis and a median survival of 10 months. With the different types of treatment for acute nonlymphocytic leukemia that are now available, we suggest that high-resolution chromosome analysis will become an important tool in selecting specific types of therapy for groups of patients with differing prognoses.
利用105例连续的初发急性非淋巴细胞白血病成年患者骨髓标本的高分辨率染色体,我们发现这种疾病存在异常高的复杂性,这可能解释了以往在确定有用的预后指标方面存在的困难。105例患者中的99例标本得到成功分析,其中92例(93%)存在染色体缺陷。共识别出17种类型,其中12种代表特定的复发性缺陷。已发现其中3种具有独立的预后重要性。根据法美英急性白血病协作组的形态学分类诊断为M2、M4或M5b型疾病且伴有16号染色体倒位的患者(9%),获得了一致且持续的完全缓解,中位生存期为25个月。相比之下,14例(14%)伴有复杂染色体异常且诊断为M1、M2、M4、M5a或M6型疾病的患者预后很差。14例患者中有12例诱导缓解的努力失败,该组的中位生存期为2.5个月。第三组以8号染色体三体作为单一缺陷(11%),预后中等,中位生存期为10个月。鉴于目前可用的不同类型的急性非淋巴细胞白血病治疗方法,我们认为高分辨率染色体分析将成为为不同预后的患者群体选择特定治疗类型的重要工具。